Tuesday, 7 October 2014
Huge levels of potentials to explore by pharmaceuticals as the high mortality rate and unavailability of effective treatments for Ebola.
Allied market research publishes a new report titled “Global Potential Analysis of Ebola drug and Vaccines Market (Pipeline analysis, Drugs, Vaccines, and Geography) through 2020.” This report provides knowledge and deep-insights on the Ebola disease from the time of its existence. The report is an extensive study on the growing need for Ebola drug market.
Ebola haemorrhagic fever (EHF) is popularly known as Ebola virus diseases (EVD). Headaches, muscle pain, sore throat and fever are most common symptoms seen in an Ebola patient. The disease is more predominant in western & central Africa and the around the tropical rain forest region. In terms of geographical analysis, report covers LAMEA, North America, Asia-Pacific and Europe. African countries have the highest number of Ebola cases and with the wide presence of African population in America, the US government is implementing strong regulations in order to control this disease.
“Additionally, the governments in the developed countries have also taken formidable steps to support the research activities for the development of EVD therapeutics by providing funding and floating favourable policies. As an example, Tekmira Pharmaceuticals has received fast-track designation from U.S. food and drug administration for their anti-ebola therapeutic TKM-ebola. In 2012, Serepata Therapeutics had also received fast track designation for AVI-7537, a lead drug candidate for EVD. Both these companies are developing their anti-ebola products under the contract of the U.S. department of defence (DoD),” says AMR analysts Roshan Deshmukh.
“Due to high mortality rate and unavailability of effective treatments, the pharmaceutical companies have big opportunities to explore. Tekmira Pharmaceuticals, BioCryst Pharmaceutical Inc., Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceutical are some of the leading companies focusing on research activities to develop efficacious medicine for EVD,” adds Deshmukh.